CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Revenues:
Total revenues	$ 1,700,320	$ 431,516	$ 5,988,003	$ 1,617,508
Cost of revenues	550,457	154,804	1,149,629	566,417
Operating expenses:
Selling, general and administrative	3,239,953	2,589,042	10,298,343	7,247,999
Research and development	1,029,627	814,599	2,652,047	2,082,043
Depreciation and amortization	247,771	61,865	544,564	203,469
Total operating expenses	4,517,351	3,465,506	13,494,954	9,533,511
LOSS FROM OPERATIONS	(3,367,488)	(3,188,794)	(8,656,580)	(8,482,420)
Other (expense) income:
Interest income (expense), net	3,572	(28,624)	11,975	(86,811)
Loss on extinguishment of convertible notes payable			(1,774,662)	0
Gain on extinguishment of notes payable			839,945	0
Other expense, net	(82,799)	(72,694)	(191,533)	(334,527)
Loss before provision for income taxes	(3,446,715)	(3,290,112)	(9,770,855)	(8,903,758)
Provision for income taxes	0	0	0	0
NET LOSS	(3,446,715)	(3,290,112)	(9,770,855)	(8,903,758)
Less: Net (income) loss attributable to noncontrolling interest	(2,278)	662	(4,494)	(528)
NET LOSS attributable to Applied DNA Sciences, Inc.	(3,448,993)	(3,289,450)	(9,775,349)	(8,904,286)
Deemed dividend related to warrant modifications				(2,842)
NET LOSS attributable to common stockholders	$ (3,448,993)	$ (3,289,450)	$ (9,775,349)	$ (8,907,128)
Net loss per share attributable to common stockholders-basic and diluted	$ (0.46)	$ (0.72)	$ (1.45)	$ (2.54)
Weighted average shares outstanding- basic and diluted	7,486,120	4,577,997	6,724,503	3,512,149
Product
Revenues:
Total revenues	$ 639,637	$ 56,911	$ 2,154,844	$ 492,582
Service
Revenues:
Total revenues	$ 1,060,683	$ 374,605	$ 3,833,159	$ 1,124,926